Anti-neoplastic agents, combination therapies and related methods
In certain aspects, the invention relates to the discovery of novel compositions for use in the treatment of a neoplastic disorder. Further aspects of the invention relate to the discovery that cell signaling may be exploited to identify significant genes in cancer cell lines and to generate reporter gene systems that may be used, for example, to identify anti-neoplastic agents and effective combinations thereof.
1 . A pharmaceutical formulation comprising:
a. a compound of the niclosamide class of compounds formulated for systemic administration; and
b. a pharmaceutically acceptable excipient.
2 . The pharmaceutical formulation of claim 1 , wherein the compound of the niclosamide class of compounds is formulated for slow release.
3 . The pharmaceutical formulation of claim 1 , further comprising a steroid signal modulator.
4 . The pharmaceutical composition of claim 1 , further comprising a cardiac glycoside.
5 . The pharmaceutical composition of claim 4 , wherein the cardiac glycoside is ouabain.
6 . A method of treating a neoplastic disorder comprising: administering a therapeutically effective amount of a compound of the niclosamide class.
7 . The method of claim 6 , wherein the neoplastic disorder is a cancer comprising a HIF-positive tumor cell.
8 . The method of claim 6 , wherein the neoplastic disorder is a cancer selected from among the following: pancreatic cancer, lung cancer, colon cancer, prostate cancer, cervical cancer, renal cancer, uterine cancer and breast cancer.
9 . A pharmaceutical formulation comprising:
a. a cardiac glycoside in an amount sufficient to decrease the expression of a HIF-responsive gene and insufficient to achieve an optimal cardiovascular therapeutic effect; and
b. a pharmaceutically acceptable excipient.
10 . The pharmaceutical composition of claim 9 , wherein the cardiac glycoside is an aglycone form.
11 . The pharmaceutical composition of claim 9 , wherein the cardiac glycoside is selected from the following: a butenolide form and a pyrone form.
12 . The pharmaceutical formulation of claim 9 , further comprising a steroid signal modulator.
13 . The pharmaceutical formulation of claim 12 , wherein the steroid signal modulator is bicalutamide.
14 . The pharmaceutical composition of claim 9 , further comprising a redox effector.
15 . The pharmaceutical composition of claim 14 , wherein the redox effector is a member of the niclosamide class of compounds.
16 . A method of treating a neoplastic disorder comprising: administering a cardiac glycoside in an amount sufficient to decrease the expression of a HIF-responsive gene and insufficient to achieve an optimal cardiovascular therapeutic effect.
17 . The method of claim 16 , wherein the neoplastic disorder is a cancer comprising a HIF-positive tumor cell.
18 . The method of claim 16 , wherein the neoplastic disorder is a cancer selected from among the following: pancreatic cancer, lung cancer, colon cancer, prostate cancer, cervical cancer, renal cancer, uterine cancer and breast cancer.
19 . The method of claim 16 , wherein the pharmaceutical composition further comprises an additional anti-neoplastic agent.
20 . The method of claim 19 , wherein the additional anti-neoplastic agent is selected from among: a cardiac glycoside, a redox effector, a steroid signal modulator and an EGF antagonist.
21 . The method of claim 20 , wherein the redox effector is selected from among: a clofazimine, an electron transport inhibitor, a cytochrome P450 inhibitor and an electron acceptor.
22 . The method of claim 20 , wherein the redox effector is selected from among: clofazimine, niclosamide, proadifen, mefloquin and menadione.
23 . The method of claim 20 , wherein the steroid signal modulator is selected from among: an estrogen agonist, a cardiac glycoside and a steroidogenesis inhibitor.
24 . The method of claim 20 , wherein the steroid signal modulator is selected from among: diethylstilbestrol; dienestrol; digitoxigenin; digoxin; lanatoside C and econazole.
25 . The method of claim 20 , wherein the steroidogenesis inhibitor is bicalutamide.
26 . The method of claim 20 , wherein the EGF antagonist is selected from among: gelfitinib and erlotinib.
27 . A pharmaceutical composition comprising:
a. a cardiac glycoside;
b. a second active ingredient selected from the group consisting of: a steroid signal modulator, a redox effector and an EGF antagonist; and
c. a pharmaceutically acceptable carrier.
28 . A cell comprising: a nucleic acid construct which includes a positive selection marker and a negative selection marker, wherein expression of the positive selection marker and the negative selection marker is regulated by extracellular signaling.